Anti-EGF Antibodies Increase the Effect of ALK and MEK Inhibitors in ALK and KRAS NSCLC and CRC Cell Lines

Simple item page
dc.contributor.authorGarcia-Roman, S.
dc.contributor.authorCodony-Servat, J.
dc.contributor.authorMolina-Vila, M.
dc.contributor.authorBertran-Alamillo, J.
dc.contributor.authorGimenez-Capitan, A.
dc.contributor.authorViteri, S.
dc.contributor.authorCardona, A.
dc.contributor.authorRodriguez-Abreu, D.
dc.contributor.authorCobo Dols, M.
dc.contributor.authorReguart, N.
dc.contributor.authorKarachaliou, N.
dc.contributor.authorD'Hondt, E.
dc.contributor.authorRosell, R.
dc.contributor.authoraffiliation[Garcia-Roman, S.] Quiron Dexeus Univ Hosp, Lab Oncol Pangaea Oncol, Drug Dev, Barcelona, Spain
dc.contributor.authoraffiliation[Codony-Servat, J.] Quiron Dexeus Univ Hosp, Lab Oncol Pangaea Oncol, Drug Dev, Barcelona, Spain
dc.contributor.authoraffiliation[Molina-Vila, M.] Quiron Dexeus Univ Hosp, Lab Oncol Pangaea Oncol, Drug Dev, Barcelona, Spain
dc.contributor.authoraffiliation[Bertran-Alamillo, J.] Quiron Dexeus Univ Hosp, Lab Oncol Pangaea Oncol, Drug Dev, Barcelona, Spain
dc.contributor.authoraffiliation[Gimenez-Capitan, A.] Quiron Dexeus Univ Hosp, Lab Oncol Pangaea Oncol, Drug Dev, Barcelona, Spain
dc.contributor.authoraffiliation[Viteri, S.] Hosp Univ Quiron Dexeus, Inst Oncol Dr Rosell IOR, Barcelona, Spain
dc.contributor.authoraffiliation[Karachaliou, N.] Hosp Univ Quiron Dexeus, Inst Oncol Dr Rosell IOR, Barcelona, Spain
dc.contributor.authoraffiliation[Cardona, A.] Inst Oncol, Med Oncol Clin & Translat Oncol Grp, Clin Country, Bogota, Colombia
dc.contributor.authoraffiliation[Rodriguez-Abreu, D.] Hosital Insular Gran Canaria, Med Oncol, Las Palmas Gran Canaria, Spain
dc.contributor.authoraffiliation[Cobo Dols, M.] Hosp Reg Univ Carlos Haya, Gen Hosp, Malaga, Spain
dc.contributor.authoraffiliation[Reguart, N.] Hosp Clin Translat Genom & Targeted Therapeut Sol, Inst Invest Biomed August Pi & Sunyer Idibaps, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[D'Hondt, E.] Bioven Europe Ltd, London, England
dc.contributor.authoraffiliation[Rosell, R.] Germans Trias & Pujol Hlth Sci Inst & Hosp, Catalan Inst Oncol, Canc Biol & Precis Med Program, Barcelona, Spain
dc.date.accessioned2025-01-07T12:14:59Z
dc.date.available2025-01-07T12:14:59Z
dc.date.issued2018-10-01
dc.identifier.doi10.1016/j.jtho.2018.08.857
dc.identifier.essn1556-1380
dc.identifier.issn1556-0864
dc.identifier.unpaywallURLhttp://www.jto.org/article/S155608641831815X/pdf
dc.identifier.urihttps://hdl.handle.net/10668/24368
dc.identifier.wosID454014502013
dc.issue.number10
dc.issue.numberS
dc.journal.titleJournal of thoracic oncology
dc.journal.titleabbreviationJ. thorac. oncol.
dc.language.isoen
dc.organizationSAS - Hospital Universitario Regional de Málaga
dc.page.numberS582-S582
dc.publisherElsevier science inc
dc.rights.accessRightsopen access
dc.subjectEGF
dc.subjectVaccine
dc.subjectImmunotherapy
dc.titleAnti-EGF Antibodies Increase the Effect of ALK and MEK Inhibitors in ALK and KRAS NSCLC and CRC Cell Lines
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number13
dc.wostypeMeeting Abstract

Files

Collections

Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud (FIMABIS)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía